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Abstract—Neurodegenerative diseases such as Alzheimer, Parkinson, amyotrophic lateral sclerosis, and
Huntington are incurable and debilitating conditions that result in progressive death of the neurons. The
definite diagnosis of a neurodegenerative disorder is disadvantaged by the difficulty in obtaining biop-
sies and thereby to validate the clinical diagnosis with pathological results. Biomarkers are valuable i-
ndicators for detecting different phases of a disease such as prevention, early onset, treatment, progres-
sion, andmonitoring the effect of pharmacological responses to a therapeutic intervention. Inflammation
occurs in neurodegenerative diseases, and identification and validation of molecules involved in this
process could be a strategy for finding new biomarkers. The ideal inflammatory biomarker needs to be
easily measurable, must be reproducible, not subject to wide variation in the population, and unaffected
by external factors. Our review summarizes the most important inflammation biomarkers currently a-
vailable, whose specificity could be utilized for identifying andmonitoring distinctive phases of different
neurodegenerative diseases.
KEYWORDS: Alzheimer disease; Parkinson disease; amyotrophic lateral sclerosis; Huntington disease; inflammatory
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INTRODUCTION
In response to tissue damage caused by trauma or
infection, the inflammatory response sets in as a complex
network of molecular and cellular interactions directed to
facilitate a return to physiological homeostasis and tissue
repair. Inflammation is well defined as a localized re-
sponse, but with systemic consequences caused by injury
or tissue damage, which helps to destroy, reduce, or se-
quester both the harmful agent and the damaged tissue.
Inflammation is well defined as a localized response, but
with systemic consequences elicited by injury or tissue
damage, which helps to destroy, reduce, or sequester both
the harmful agent and the wounded tissue. It is character-
ized in the acute form by the classical signs of pain (dolor),
heat (calor), redness (rubor), swelling (tumor), and loss of
function (functio laesa). From a histological point of view,
it involves a complex series of events, including vasodila-
tation of post-capillary veins, with increased permeability
and blood flow, exudation of fluids, and plasma proteins
and leukocyte migration into the inflammatory focus. In-
flammation becomes a chronic condition that continuously
damages the surrounding tissues in the cases in which the
healthy tissue is not restored or in response to stable low-
grade irritation. Neurodegenerative diseases are a group of
chronic, progressive disorders characterized by the gradual
loss of neurons in discrete areas of the central nervous
system. Particular portions of the brain, spinal cord, or
peripheral nerves are affected. Depending on the neurode-
generative disease, it can disturb cognition, movement,
strength, coordination, sensation, or autonomic control.
Inflammation is a common feature in neurodegenerative
diseases. While inflammation may not be the event initiat-
ing neurodegeneration, there is evidence that chronic in-
flammation involving microglia and astrocytes activation
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contributes to disease progression. The inflammatory re-
sponse has been implicated in several neurodegenerative
diseases such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington disease (HD), and amyotrophic
lateral sclerosis (ALS). Currently, a major question concerns
whether inhibition of the inflammatory response can reverse
or slow the symptoms of disease [1, 2]. In general, inflam-
mation may have beneficial and/or injurious effects in some
particular disease and/or in a particular phase of a disease.
However, in neurodegenerative diseases chronic inflamma-
tion causes death/loss of neurons. In fact, there is evidence
that brain inflammation may contribute to triggering off the
pathology of neurodegenerative diseases including AD, PD,
HD, and ALS [3–5]. These pathologies have different
causes and consequences, and there is evidence that block-
ing inflammation can either delay onset or reduce symptoms
[6]. Microglia can have three different morphologies: rest-
ing, activated, and amoeboid/phagocytic. The healthy, non-
inflamed brain contains almost entirely “resting” microglia
which are highly ramified, with a small, static cell body, but
with dynamic and branched processes actively seeking out
pathogens and damage in the brain [7]. Depending on the
pathology, different pathways contribute to neurodegenera-
tive processes activated by inflammation. Factors released
from damaged neurons such as α-synuclein in PD, deposits
of amyloid aggregates in AD, and SOD1 in ASL trigger
activation of microglia and astrocytes which, in turn, release
pro-inflammatory molecules. Furthermore, inflammation
leads to enhanced levels of oxidative stress; astrocytes re-
lease ROS and NO that, together with NADPH oxidase
stimulation, provoke microglia activation. Subsequently,
activated microglia may secrete signals to recruit CD4+
CD25+ T cells, which directly affect neurons via Fas/Fas–
ligand interaction. However, other events, such as
mitochondrial dysfunction, protein aggregation, glutamate
excitotoxicity, and loss of trophic factor support, may
promote neuronal cell death. For instance, tumor necrosis
factor-α (TNF-α), a major pro-inflammatory cytokine,
activates microglia and cause neurotoxicity in motor
neurons. The inflammatory mediators such as TNF-α, IL-
1β, and IL6 derived from non-neuronal cells including
microglia modulate the progression of neuronal cell death
in neurodegenerative disease. Apoptosis and necrosis of
neurons result in the release of ATP, which further
activates microglia through the purinergic P2X7 receptor
[1] (Fig. 1). Due to the extensive involvement of the
inflammatory process in brain disorder, it is clear that the
identification of biomarkers within the inflammatory
process is of paramount importance. Biomarkers are a
most important tool for an accurate diagnosis and
prognosis of a disease and for monitoring the effect of
therapeutic intervention [8]. Many unsuccessful efforts
have been done to find a biomarker that fulfills the criteria
of an ideal biomarker specific for neurodegenerative
disease. There are some technical limitations in identifying
low abundant cytokines, and many factors likely influence
immune markers, such as concomitant infection and
inflammatory illness. Furthermore, the levels of many
biomarkers such as cytokines have been shown to display
daily variation and different alterations caused, for example,
by the storage of the samples, and standardization of pre-
analytical procedures is fundamental to obtain reproducible
results. On the basis of this experience, in the research and
validation of new biomarkers some criteria must be
considered and standardized such as healthy controls,
clinical diagnosis and verification, publication, and
validation by multicenter studies. Finally, the development
of new technologies is now permitting to overcome
some of these problems for screening and discovering
new biomarkers. Different biomarkers identified in the
main neurodegenerative diseases are summarized in
Table 1.
ALZHEIMER’S DISEASE
Alzheimer’s disease is a heterogeneous and progres-
sive neurodegenerative disease that in western societies
accounts for 60 to 80 % of all dementia cases. Age is the
first and primary risk factor in AD. Prevalence of AD
increases exponentially with age, rising from 3 % among
individuals between 65 and 74 years to almost 50% among
those from 85 years or older [9]. Hebert et al. estimated that
the total number of people with AD dementia in 2050
would be 13.8 million, with 7.0 million aged 85 years or
older [10]. The genetics of AD is complex and heteroge-
neous. Most cases are “sporadic” with no apparent familial
recurrence of the disease. However, a small percentage of
AD cases (1–2 % of all cases) have an early onset, with
symptoms appearing before 65 years of age [11]. Neuro-
pathological hallmarks are neuritic amyloid plaques and
neurofibrillary tangles. Amyloid is a general term for pro-
tein fragments that the body produces normally. Beta am-
yloid (Aβ) is a protein fragment obtained from the amyloid
precursor protein (APP) after cleavage of two specific
secretases. In a healthy brain, these protein fragments are
broken down and eliminated. In Alzheimer’s disease, the
fragments are misfolded and aggregate to form oligomers,
fibrils and form hard, insoluble plaques. Extracellular se-
nile plaques result from the accumulation of several
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proteins and an inflammatory reaction around deposits of
amyloid proteins. Neurofibrillary tangles are intracellular
deposits of hyperphosphorylated degenerate filaments,
which result from aggregations of the microtubular protein
tau. As these cellular changes progress, neurons are lost in
the hippocampus, entorhinal cortex, and associated areas of
the neocortex. The clinical hallmarks of AD are progres-
sive impairment in memory, judgment, decision-making,
orientation to physical surroundings, and language togeth-
er with changes in personality, behavior or comportment,
which cause a significant interference in the ability to
function at work or in usual daily activities [12]. Immuno-
histochemical studies have shown that the plaques and
tangles of AD are heavily infiltrated with activated glial
cells and inflammatory factors. Cytokines, chemokines,
complement components, and acute phase proteins are
co-localized as secondary components in senile plaques
or are over-produced in AD brains [13]. Activated glial
cells surround the depositions of amyloid attempting to
phagocyte and degrading amyloid component. Microglia
cells recruit astrocytes too, activating them. Following
activation, both cell types produce acute-phase proteins,
complement components, prostaglandins, and cytokines.
Actually, microglia cells are a high producer of free radi-
cals and generation of reactive oxygen species (ROS)
Fig. 1. A model of the different inflammatory pathways involved in neurodegenerative disease. Factors involved in neurodegenerative diseases such as α-
synuclein in PD (α-SYN), deposit of amyloid aggregates in AD (Aβ), SOD1 in ASL (SOD1), and Huntingtin (HTT) in HD trigger activation of microglia.
Activated microglia release pro-inflammatory molecules (IL-1β, IL6, FASL, and TNF-α). Inflammation leads to oxidative stress and release of ROS and
NO, through NADPH oxidase and iNos stimulation, inducing neuronal death via apoptosis and/or necrosis. A consequence is the release of ATP, which
activates microglia through the purinergic P2X7 receptor. Activated microglia secretes signals to recruit CD4+ CD25+ T cells, which directly affect neurons
via Fas/Fas–ligand interaction. BBB blood–brain barrier.
Table 1. Inflammatory Biomarker Studies of Prospective Cognitive De-
cline in Neurodegenerative Disease
Biomarker Study cohort Reference
Alzheimer disease
Interleukin-8 48 patients Zhang 2008 [28]
s100B 31 patients Petzold 2003 [19]
18 markers in blood 2,007 patients Doecke 2012 [29]
Complement component, Serpin
G1 Ser/cYS protease inhibitor,
Serpin G1 plasma protease
C1 inhibitor
7 patients Henkel 2012 [31]
Parkinson disease
IL-6 84 patients Chen 2008 [43]
Fibrinogen 61 patients Wong 2010
miRNA 7 patients Margis 2011 [45]
Amyotrophic lateral sclerosis disease
TDP-43, cycl A, ERp57 23 patients Nardo 2011 [62]
MMP-9 25 patients Beuche 2000 [65]
Huntington disease
Cytokine IL-6 194 patients Bjökqvist 2008 [72]
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contributes to damage neurons. Since Aβ represents a
pathogenetic molecule, the innate immune system makes
an initial attempt to protect the brain by clearing these
potentially toxic products. The hypothesis is that the com-
plex nature of the plaques and tangles stimulates a chronic
inflammatory reaction to scavenge this debris. Chronically
activatedmicroglia and astrocytes can kill adjacent neurons
by the release of highly toxic products such as reactive
oxygen intermediates, nitric oxide, proteolytic enzymes,
complement factors or excitatory amino acids. Microglia
cells activation in AD can be due to the binding of Aβ to
the CD14 receptor and its co-receptor TLR4 [14]. Cere-
brospinal fluid (CSF) is a fluid that circulates throughout
the central nervous system (CNS) and is located between
the brain and skull. It is produced in the brain and can
therefore be considered a window onto the brain. The CSF
is in direct contact with the extracellular space of the brain
and can reflect biochemical changes occurring in the latter.
Attention to CSF biomarkers is important in the treatment
of patients to assess in vivo pathology, even if the use of
CSF is limited because it is considered an invasive collec-
tion method. In particular, interleukins-2, -3, and 6, trans-
forming growth factor β1 (TGFβ1), interferon-α, heparin
binding growth-associated molecule, nitric oxide synthase,
macrophage-colony stimulating factor, interleukin-8 recep-
tor B, monocyte chemoattractant protein-1, the beta-che-
mokine receptors CCR3 and CCR5 and macrophage in-
flammatory protein-1β (MCP1), fibroblast growth factor-
9, vascular endothelial growth factor, and the interferon γ-
inducible chemokine IP-10 were found [15]. A studied
inflammatory biomarker is α1-antichymotrypsin
(A1ACT). It is secreted by astroglial cells and can co-
localize with Aβ in plaques of AD, and is observed either
increased [16] or unchanged [17] in CSF samples of AD
patients. However, the contradictory results suggest that
more studies must be conducted before that A1ACTcan be
regarded as an effective biomarker. A study comparing
levels of s100B, a protein secreted by astrocytes, in the
CSF of AD patients and healthy controls found increased
levels of s100B in mild-to-moderate AD, but not in severe
AD [18]. This raises the possibility that s100B is an index
of astrocytic process involved in the earlier stages of AD,
possibly accompanying plaque maturation. In another
study, s100B was increased in CSF to a similar extent in
AD and fronto-temporal dementia relative to controls [19].
Interleukin-8 (IL-8) receptor has been localized in dystro-
phic neurites, suggesting that IL-8 mediates glial interac-
tions with neurons and thereby contributes to neuronal
damage [20]. IL-8 was significantly increased in CSF of
AD patients compared to healthy controls [21], whereas
plasma levels of IL-8 in late-onset AD and vascular de-
mentia did not differ from controls [22]. Transforming
growth factorβ (TGFβ) is an important astrocyte-derived
cytokine, induced by IL-1, that manifests both pro-inflam-
matory and anti-inflammatory properties. Brain tissue lev-
els of TGFβ and TGFβ mRNAs increase in AD [23]. A
number of reports published between 1990s and early
2000s describe alterations in the levels of various cyto-
kines, markers of oxidative stress and inflammatory mole-
cules in CSF. However, results were very inconsistent,
probably owing to differences in methodology, CSF col-
lection and processing, assays, subject ascertainment, prev-
alence of comorbidities and methods of diagnosis. Unbi-
ased proteomics methods have more recently been used to
identify molecules that diverge between dementia of the
Alzheimer type and control CSF. These studies have con-
sistently identified a plethora of inflammatory markers that
differ in abundance between clinical groups [24–26]. How-
ever, even in these unbiased screens, the direction of
reported difference in abundance has not been consistent.
In contrast to CSF, blood samples are much easier to
obtain, but concentrations of most potential neuronal bio-
markers are several fold lower in blood than in CSF [27].
Besides such practical problems, there are intrinsic diffi-
culties encountered when blood serum or plasma samples
are analyzed because the blood proteome contains large
quantities of high-abundance proteins, which have most
likely no direct reference to the pathological process. Given
the multiplicity of pathophysiological processes implicated
in AD, a combination of biomarkers related to different
mechanisms might increase diagnostic accuracy. Several
studies focusing on combinations of blood-based bio-
markers have yielded positive results. Ray et al. used
combined multivariate analysis of 18 plasma signaling
and inflammatory proteins to identify AD patients and
predict future AD with high accuracy in mild cognitive
impairment (MCI) patients [28]. This protein panel was
identified after screening of a large number of known
proteins using a filter-based protein array. More recently,
two research groups have found multi-marker panels able
to distinguish unhealthy from healthy individuals. In one
report, Martins and colleagues [29] found that a set of 18
markers in blood had sensitivity and specificity of more
than 80 % for distinguishing patients with Alzheimer’s
disease from healthy controls. In a biomarker panel, sig-
nificantly increased levels of cortisol, pancreatic polypep-
tide, insulin-like growth factor binding protein 2, β2
microglobulin, vascular cell adhesion molecule 1, carci-
noembryonic antigen, matrix metalloprotein 2, CD40,
macrophage inflammatory protein 1α, superoxide
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dismutase, and homocysteine, and decreased levels of apo-
lipoprotein E, epidermal growth factor receptor, hemoglo-
bin, calcium, zinc, interleukin 17, and albumin were found
in samples of AD patients. The other report, by Holly
Soares and colleagues, indicated that a mainly different
set of markers associated with the apolipoprotein E geno-
type such as eotaxin 3, pancreatic polypeptide, and N-
terminal protein B-type brain natriuretic peptide, C-reac-
tive protein, cortisol, interleukin 13, apolipoprotein B, and
gamma interferon were increased both in patients with
Alzheimer’s disease and MCI. Plasma biomarker results
confirm CSF studies reporting increased levels of pancre-
atic polypeptide and N-terminal protein B-type brain natri-
uretic peptide in patients with AD and MCI. Incorporation
of plasma biomarkers yielded high sensitivity with im-
proved specificity, supporting their usefulness as a screen-
ing tool [30]. Recently, new analytical proteomic technol-
ogies like MS coupled with protein separation or protein
microarrays, which can be applied on CSF and other body
fluids, have been developed to study proteins in neurosci-
ence. Henkel et al. removed 12 high-abundance proteins
from plasma and labeled the depleted samples from AD
patients and disease controls with different fluorescent
dyes, mixed the samples, and separated them by anionic
exchange and RP chromatography. The resulting chroma-
tography fractions were analyzed on 2D gels. They identi-
fied 20 significant differentially expressed proteins through
MS analysis, some known to be involved in inflammatory
processes: three members of the complement system (C1S,
C6 complement component six precursor, and CFH iso-
form one of complement factor H), SerpinG1 Ser/Cys
protease inhibitor, and Serpin G1 plasma protease C1
inhibitor [31]. However, in the research of new biomarkers
for AD, it will become extremely important in the future to
find also markers able to differentiate AD from other forms
of dementia.
PARKINSON’S DISEASE
Parkinson’s disease (PD) is a progressive neurode-
generative pathology characterized by motor manifesta-
tions. Its prevalence increases with age, being approxi-
mately 1 % in people over the age of 60 and increasing
to about 4 % over the age of 85 [32]. The etiology is still
unknown [33], but it has been hypothesized that the onset
of PD may be the result of a complex interaction among
environmental factors, genetic susceptibility, and aging
[34, 35]. The pathological hallmark of PD comprises loss
of nigrostriatal dopaminergic neurons in the substantia
nigra (SN) pars compacta (SNc) and the presence of insol-
uble protein inclusions, termed Lewy bodies (LBs) and
Lewy neurites (LNs), located in either the neuronal cell
bodies or neuronal processes, respectively [35–37]. The
major constituent of LBs and LNs is a misfolded version of
the protein alpha-synuclein (α-syn) [37]. Diagnosed
patients are characterized by motor and non-motor clinical
manifestations. The motor symptoms include resting trem-
or, bradykinesia, akinesia, muscular rigidity, and a loss of
balance [38]. These symptoms are predominantly attribut-
ed to lack of dopamine (DA) in the striatum and to the
resulting dysfunction of the basal ganglia, a cluster of
nuclei involved in the initiation and execution of move-
ment [38, 39]. Several lines of evidence suggest that in-
flammatory mediators such as ROS, NO, TNF-α, and
interleukin (IL)-1β derived from non-neuronal cells in-
cluding microglia modulate the progression of neuronal
cell death in PD [40]. A direct effect of a-synuclein on
microglia (as opposed to a TLR-dependent pathway as
observed following LPS treatment) has been demonstrated.
In fact, extracellularα-synuclein is phagocytized bymicro-
glia, resulting in activation of NADPH oxidase and ROS
production. NADPH oxidase activation and ROS produc-
tion are a crucial mechanism for microglia activation after
exposure to α-synuclein as the toxic effect was less strong
in mice lacking NADPH oxidase [41]. The oxidative stress
induced by α-synuclein is a potent inducer of microglia in
vitro and in vivo and is associated with activation of NFkB-
related genes and increased expression of neurotrophins
such as NFKB1, TNF, TNFRSF1A, BDNF, and GDNF
[42]. Furthermore, activated microglia may secrete signals
to recruit CD4+ T cells, which directly affect neurons via
Fas/Fas–ligand interaction.Moreover, nitratedα-synuclein
may activate CD4+ and CD4+ CD25+ Tcells, and then they
interact with microglia to initiate microgliosis and immune
responses. Some other events, such as mitochondrial
dys func t ion , p ro te in aggrega t ion , g lu tamate
excitotoxicity, and loss of trophic factor support, may
also promote death of dopaminergic neurons. Several
biomarkers have been associated with cognitive
impairment in PD in longitudinal studies. Two recent
studies have attempted to determine the predictive value
of prediagnostic levels of inflammation on future PD risk.
In one study [43], investigators observed an association
between IL-6 concentrations and higher PD risk but no
found any association with other markers of inflammation
including C-reactive protein (CRP), fibrinogen, or TNF-α.
In the other study, higher levels of fibrinogen were
associated with higher PD risk among men of Japanese
ancestry [44]. Chen and co-workers concluded that men
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with high plasma concentrations of IL-6 have an increased
risk of developing PD. An innovative study of miRNAs in
blood samples from a healthy control group, untreated
early-onset PD, and PD patients undergoing treatment
identified six differentially expressed miRNAs. Whereas
miR-1, miR-22, and miR-29 expression levels
distinguished untreated PD from healthy patients, miR-
16-2, miR-26a2, and miR30a differentiated treated PD
patients from untreated patients [45], suggesting a
potential approach to evaluate drug response. Moreover,
careful CSF studies using a sophisticated metabolomics
analysis platform have revealed PD-specific fingerprints
with an increased xanthine/homovallinic acid ratio in PD
compared with controls. This ratio correlated with disease
severity making it a good candidate for both diagnostic and
surveillance purposes [46, 47]. The search for effective
biomarkers for diagnosis and surveillance of PD continues.
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis is an incurable neuro-
degenerative disorder of unknown cause arising from pro-
gressive degeneration of motor neurons and resulting in
paralysis and death, usually within 3–5 years from diagno-
sis. Its incidence is between 1.5 and 2.5 per 100,000 per
year: approximately 90 % of cases are sporadic and the
remaining 10 % are familial. In the familial ALS (fALS), a
number of causative genes were identified. The first gene
identified was Cu/Zn superoxide dismutase 1 (SOD1),
which has numerous different mutations [48]. Other genes
implicated in fALS are fused in sarcoma protein (FUS)
[49] and tar-DNA binding protein of molecular weight
43 kDa (TDP 43) [50]. For the diagnosis of ALS, there
are strict clinical definitions [51] that involve the finding of
a combination of upper and lower motor neuron signs.
Moreover, the clinical course varies widely. At first pre-
sentation, some patients do not fulfill these strict criteria,
but as time goes by they develop additional signs that
confirm the diagnosis [52]. Neuro-inflammation is a prom-
inent pathological feature in ALS. The importance of glial
cell activation and pro-inflammatory cytokines in ALS has
been confirmed by numerous studies. For instance, TNF-
α, a major pro-inflammatory cytokine, activates microglia
and causes neurotoxicity in motor neurons. Expression of
mutant SOD1 in microglia leads to ROS production and
secretion of TNF-α and the metalloproteinases (AD-
AM10–17) suggesting a role for oxidative stress in
neuro-inflammation in ALS [53]. It is possible that degen-
erating neurons in the spinal cords of ALS patients release
ATP activating glial cells and inducing astrocytic puriner-
gic (P2X7) receptors to release IL-1β [54]. In addition,
FUS/TLS is a coactivator of NF-κB, which may be in-
volved in the inflammatory response [55, 56]. Therefore,
TLRs and purinergic receptors may serve as sensors for
candidate transcription factors, including activator protein-
1 (AP-1) and NF-κB. Increased levels of ROS, inflamma-
tory mediators such as COX-2, and proinflammatory cyto-
kines such as IL-1β, TNF-α, and IL-6 characterize glia
activation [57]. Further investigations are required to better
understand the role of inflammation in the CNS of ALS
patients. Moreover, there have been numerous studies in-
vestigating peripheral immune abnormalities in ALS. With
respect to T-cell abnormalities, in the blood of individuals
with ALS, it has been reported that there is an increased
number of CD4+ T-helper cells and expression of HLA
class II molecules on monocytes and macrophages,
suggesting activation of immune system [58]. Another
study found increased CD4+ cells, reduced regulatory T
cells (Treg), and expression of HLA DR in monocytes
[59]. There are increased levels of circulating chemokines
and cytokines in ALS. Other markers of inflammation are
also abnormal in ALS. There is also evidence of low-level
systemic inflammation with increased levels of C-reactive
protein and ESR in patients with ALS compared to
controls, with the levels correlating to disability as
measured by the ALS functional rating scale [60]. All
these studies demonstrate the presence of a systemic
immune response in people affected by ALS. No ALS
biomarkers and molecular diagnosis are currently in
clinical use, but they would be valuable to support early
diagnosis, monitor disease progression, and assess the
efficacy of any new treatment [61]. Nardo et al. used a
proteomic approach (using peripheral blood mononuclear
cells, PBMC) to identify a panel of protein biomarkers that
are closely associated with ALS. Their results indicate that
PBMC multiprotein biomarkers could contribute to ALS
diagnosis, severity, and progression. Validation and a
longitudinal study were performed by immunoassays on
a selected number of proteins. The same proteins were also
measured in PBMC and spinal cord of a G93A SOD1
transgenic rat model. Their multiprotein biomarkers can
distinguish ALS patients from healthy controls (98 %) and
from patients with neurological disorders that may
resemble ALS (91 %). They demonstrated that TDP-43,
cyclophilin A, and ERp57 were associated with disease
progression in a longitudinal study. Moreover, there are
higher levels of the chemokine MCP-1 in patients with a
shorter diagnostic delay, which is a marker of more severe
disease progression disease [62]. Ching-Hua Lu showed
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that plasma neurofilament heavy chain (NfH) levels
closely reflect later stages of disease progression and
therapeutic response in the SOD1 G93A mouse model of
ALS and may potentially be a valuable biomarker of later
disease progression in ALS [63]. Mitchell et al. reported a
cytokine profile in the CSF of ALS patients using luminex
multiplex assay. A five cytokines panel could predict ALS
with 89 % accuracy in a set of 74 subjects. However, since
altered cytokines expression occurs during inflammation,
further verification and validation studies with additional
disease mimics are required to determine the specificity of
this CSF cytokines panel for ALS [64]. Finally, Beuche et
al. demonstrated that matrix metalloproteinase-9 (MMP-9)
is elevated in serum of patients with ALS, indicating a
potentiality to be employed as biomarker [65].
HUNTINGTON’S DISEASE
Huntington’s disease or Huntington’s chorea is a devas-
tating neurodegenerative disorder whose main hallmark is
brain atrophy. It is characterized by various clinical symptoms
and signs including cognitive dysfunction with a particular
impairment of executive functioning; psychiatric and behav-
ioral traits with frequent suicidal ideation; and motor abnor-
malities, the so-called choreic movements which are contin-
uous, random, brief, involuntary limb and orofacial muscle
contractions [66]. Typical onset is between 35 and 45 years of
age, but onsets from 2 to 85 years of age have been reported.
Patients usually die 10–15 years after the beginning of symp-
toms due to bulbar dysfunction and complications. HD is of
genetic origin and caused by a mutation in the huntingtin
gene, by expansion of a CAG repeat, which is translated into
a polyglutamine (polyQ) stretch in exon-1 (HDx1) of Hun-
tingtin (Htt). In most animal and cellular models of HD, the
neurotoxicity of mutant Htt is enhanced by the cleavage and
production of N-terminal fragments, which are generated by
various enzymes including caspases and calpains. The N-
terminal mutant Htt fragments also form amorphous intracel-
lular aggregates and accumulate in HD brain, but the role of
these aggregates in the pathobiology of HD remains a mys-
terious area of investigation. Wild-type Htt is also cleaved by
similar proteases, which can lower its level and interfere with
its vital function in neurons. Although expansion of polyQ is
a determinant in HD, the age of disease onset is variable
among patients with similar polyQ length, thus, other genetic
or environmental factors may regulate the onset and progres-
sion ofHD [67]. Several mechanisms have been implicated in
HDpathogenesis, including (1) disruption of axonal transport,
(2) excitotoxicity via NMDA receptors, (3) Htt exp-mediated
cytoplasmic sequestration of transcription factors, and (4)
mitochondrial/bioenergetic dysfunction [68–71]. None of
them are mutually exclusive, and most likely a combination
of processes leads to the pathology observed inHD.By use of
predictive genetic testing, it is possible to identify individuals
who carry the gene defect before the onset of symptoms,
providing a window of opportunity for intervention aimed
at preventing or delaying disease onset. However, without
robust and practical measures of disease progression (i.e.,
biomarkers), the efficacy of therapeutic interventions in Hun-
tington’s disease population cannot be readily evaluated.
Although neuroinflammation, signified by activated
microglia and elevated levels of pro-inflammatory cytokines,
is a component of major neurodegenerative disorders, its role
in these disorders is not well characterized, but the possibility
to develop neuroinflammation biomarkers has been explored.
HD patients express increased levels of the inflammatory
cytokine IL-6 in the serum and CNS many years before the
onset of symptoms, and its level correlates with disease
development [72]. Furthermore, post-mortem studies of HD
brains also indicate abnormal levels of several inflammatory
mediators, including CCL2, IL-10, IL-6, IL-8, andMMP-9 in
various brain regions. The IKK/NF-κB pathway, the main
inducer of these inflammatory mediators, is deregulated in
HD. IKKβ in neuroinflammation may cause both elevated
cytokine levels in the CNS and abnormal level of inflamma-
tory mediators in HD patient’s serum. Curiously, the relation-
ship between peripheral inflammation and CNS pathology in
HD is unknown. Inflammatory changes in the CNS and
peripheral tissues in HD may be due to independent effects
of mutant huntingtin in both compartments, causing analo-
gous derangements centrally and peripherally; or inflamma-
tory activationmay begin peripherally and spread to the CNS,
or vice versa, through the passage of immunomodulatory
molecules across the blood–brain barrier.
In the CNS of a R6/2 genetic mouse model of HD,
which expresses a toxic N-terminal fragment of mutant Htt
(HDx1), elevated IKKβ activity is widespread [73]. These
animals also express high levels of inflammatory cytokines
including IL-6, IL-1β, and TNF-α in the serum and CNS,
which is consistent with a deregulated IKKβ/NF-κB path-
way [72]. A recent study [74] supports a role for IKKβ in
neuroinflammation and highlights that imbalances in
IKKβ activity may be the underlying cause of elevated
cytokines in the CNS of HD patients. In these works, the
authors observed that the inhibition of caspase-mediated
maturation of IL-1β enhances neuroinflammation and neu-
rotoxicity in a mouse model and the lowering of IKKβ in
microglia reduces inflammation and neurotoxicity in to
kainic acid-induced excitotoxicity model of HD. Indeed,
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they display exaggerated IKKβ/NF-κB activity when stim-
ulated with cytokines known to activate IKKβ. The dom-
inant evidence indicates that suppressing IKKβ activity
may prevent disease progression in HD and may lower
the production of inflammatory cytokines. Thus, exploring
the effects of IKKβ inhibitors in animal models of HD
could lead to development of novel therapeutics. However,
the strategies should be developed to selectively inhibit
IKKβ in the brain due to the importance of IKKβ in
immune cell development and survival. Some changes
have been noted in the CSF of HD patients, including
monoamine metabolites and a tryptophan pathway metab-
olite [75–78]. However, current progress in the develop-
ment of biomarkers has been done and their potential in
clinical use and value in the development of future treat-
ments for patients with HD is encouraging.
CONCLUSION
Neurodegenerative diseases representmajor unmet chal-
lenges for therapeutic interventions. Characterization and tar-
geting of the processes initiating specific pathologies act
primarily at the level of neurons and are clearly an important
area for continued investigation. The emerging evidence for
both protective and pathogenic roles of microglia and astro-
cytes and the activation of common inflammation pathways
in these cells in several neurodegenerative diseases supports
the concept that glia-induced inflammation is an amplifier of
the pathology. Given the extensive involvement of the inflam-
matory process, the identification of biomarkers from inflam-
mation processmight be useful not only for diagnosis but also
for prediction of individual response to medications and the
rate of progression. Combination of inflammatory biomarkers
might be required to achieve high sensitivity and specificity.
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